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Summary
Objective To document utilization of lipid-lowering
therapy, attainment of low-density lipoprotein choles-
terol target values, and cardiovascular outcomes in
patients hospitalized for acute coronary syndrome in
Germany.
Methods The Dyslipidemia International Study II was
a multicenter, observational study of the prevalence
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of dyslipidemia and lipid target value attainment
in patients surviving any acute coronary syndrome
event. Among patients on lipid-lowering therapy
for ≥3 months, use of lipid-lowering therapy and
lipid profiles were assessed at admission and again
at 120± 15 days after admission (the follow-up time
point). Multivariate logistic regression was used to
identify variables predictive of low-density lipopro-
tein cholesterol target value attainment in patients
using lipid-lowering therapy.
Results A total of 461 patients hospitalized for acute
coronary syndrome were identified, 270 (58.6%) of
whom were on lipid-lowering therapy at admission.
Among patients on lipid-lowering therapy, 90.7% and
85.9% were receiving statin monotherapy at admis-
sion and follow-up, respectively. Mean (SD) low-
density lipoprotein cholesterol levels in patients on
lipid-lowering therapy were 101 (40) mg/dl and 95
(30) mg/dl at admission and follow-up, respectively.
In patients with data at both admission and follow-
up (n= 61), low-density lipoprotein cholesterol tar-
get value attainment rates were the same (19.7%)
at both time points. Smoking was associated with
a 77% lower likelihood of attaining the low-density
lipoprotein cholesterol target value.
Conclusion Hospitalization for an acute event does
not greatly alter lipid management in acute coronary
syndrome patients in Germany. Both lipid-lowering
therapy doses and rates of low-density lipoprotein
cholesterol target value attainment remained essen-
tially the same several months after the event.
Keywords Acute coronary syndrome · Myocardial in-
farction · Dyslipidemias · Cholesterol · LDL
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Introduction
Acute coronary syndrome (ACS) is a serious and life-
threatening clinical manifestation of atherosclerosis.
It is characterized by a thromboembolic event lead-
ing to a sudden reduction in blood flow to the heart
[1]. An ACS presents as one of several sub-types,
including ST segment elevation myocardial infarc-
tion (STEMI), non-ST elevation myocardial infarction
(NSTEMI), and unstable angina. European Society of
Cardiology (ESC) guidelines for the management of
ACS acknowledge that secondary prevention of car-
diovascular events requires treatment of dyslipidemia,
if present [1, 2]. Specifically, long-term treatment of
low-density lipoprotein cholesterol (LDL-C) serum
levels to a target value of <70mg/dl (1.8mmol/l) is
recommended, with high-dose statins and ezetimibe
as the preferred lipid-lowering therapy (LLT; [2, 3]).
These targets have been confirmed by the guidelines
for the management of dyslipidemia published by the
European Society of Cardiology (ESC) and the Euro-
pean Atherosclerosis Society (EAS) task force in 2011
[4].
Germany has made several improvements in the
management of cardiovascular disease risk factors in
ACS patients. Rates of treatment of dyslipidemia in
patients with a history of ACS increased from 35%
to 87% between 1995 and 2007 [5], and nationwide
implementation of smoking restrictions in 2007–2008
was followed by 13.3% and 8.1% declines, respec-
tively, in the annual rates of hospitalization for angina
pectoris and myocardial infarction (MI; [6]); however,
rates of hospitalization for MI in Germany remain
well above the median for European countries [7]. An
analysis of the German 2L registry of patients with
coronary heart disease (CHD) showed that most pa-
tients treated for dyslipidemia received low-intensity
statin regimens [8]. Not surprisingly, the Dyslipidemia
International Study (DYSIS) found that, among statin-
treated patients in Germany, 58.1% failed to attain the
LDL-C target value for high risk patients (<100mg/dl;
2.6mmol/l) [9], and a large German population-based
cross-sectional study found that among statin-treated
CHD patients, the estimated 10-year risk of a coro-
nary event was 35.1%, well above the threshold for
LLT [10].
Given the state of cardiovascular management in
Germany and the current guidelines for treatment of
ACS, the primary objective of the second DYSIS (DY-
SIS II) was to document utilization of LLT, LDL-C tar-
get value attainment, and cardiovascular health out-
comes in patients hospitalized for ACS in Germany.
Patients, materials and methods
Study design
The DYSIS II is an international, multicenter, obser-
vational study being conducted throughout Europe,
Asia, and the Middle East to determine the preva-
lence of dyslipidemias and lipid target value attain-
ment in patients with stable CHD and in patients hos-
pitalized for an ACS event. The ACS cohorts were as-
sessed longitudinally as described later. All data were
collected via a web-based data collection form using
software developed by the Institute for Heart Infarc-
tion Research (Institut für Herzinfarktforschung, IHF)
in Ludwigshafen, Germany.
In the German ACS cohort, 21 sites participated
in data collection from consecutive patients. Acute
care centers were selected to be representative of the
acute and ambulatory treatment of secondary preven-
tion in Germany. The patient recruitment period was
May 2013 to July 2014. Data were collected by clinical
examination and from medical charts at admission
to the hospital, and again via a telephone interview
at 120± 15 days after admission (the follow-up time
point). At the time of enrolment, patients were given
a booklet and instructed to take it with them when
they next visited their physician post-discharge (from
current hospitalization). The booklet was filled out
during the follow-up office visit by the physician and
registered the patient’s lipid profile and other basic
patient characteristics. The information in the book-
let was to be used by the patient during the follow-up
telephone interview. The protocol was approved by
local and regional institutional review boards as per
local regulations.
Study sample
Patients included in the current analysis were≥18 years
of age, had been hospitalized for ACS in Germany, and
had a full lipid profile based on blood drawn within
24h of admission. Patients must have been on LLT
for ≥3 months, or not taking LLT at all, at the time
of admission to the hospital. Patients taking LLT for
<3 months were excluded from the analysis. Each
patient provided written informed consent specifying
non-participation in any randomized clinical trials
and would not do so for the duration of the study.
Study definitions and outcome variables
In this study, ACS was defined as one or more of the
following events: STEMI/left bundle branch block
(LBBB), NSTEMI, or unstable angina. Demographic
and clinical characteristics collected at admission
included age, gender, body mass index, sedentary
life style, smoking status, and family history of CHD.
Comorbidities (e.g., hypertension, type 2 diabetes
mellitus) and cardiovascular history (of CHD, MI,
chronic renal failure, chronic kidney disease, stroke,
or peripheral vascular disease) were also recorded.
Obesity was defined according to the World Health
Organization (WHO) criteria as having a body mass
index >30kg/m2. Hypertension was defined as cur-
rent antihypertensive treatment, a previous diagnosis,
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or having blood pressure >140/90mmHg. Similarly,
diabetes was defined as current treatment for dia-
betes, a previous diagnosis of diabetes, or a fasting
plasma glucose level of ≥126mg/dl. A sedentary
life style was defined as <20–30min of walking on
<3–4 days per week. Stroke was either ischemic or
hemorrhagic. Use of selected classes of cardiovascu-
lar medications (e.g., beta-blockers, calcium channel
blockers, diuretics, angiotensin-converting enzyme
(ACE) inhibitors, antiplatelet agents) and laboratory
values of hemoglobin A1c and serum glucose were
also recorded at admission.
Patients were divided into two subgroups, treated
or untreated, based on their lipid treatment status
at admission, as defined above. Use of LLTs at the
time of the lipid test was determined by chart re-
view at admission and by patient report at follow-up.
The following mutually exclusive classes of LLT were
assessed: statin monotherapy, non-statin monother-
apy, statin plus ezetimibe, and statin plus other non-
statin therapy (“other” non-statins included fibrates
and omega-3 fatty acids). The statins assessed were
simvastatin, atorvastatin, rosuvastatin, pravastatin,
lovastatin, and fluvastatin. Atorvastatin and sim-
vastatin dose equivalents were calculated based on
clinical trial data on the LDL-C-lowering efficacy of
various statins [11]. Attainment of lipid target values
was assessed among treated patients at admission and
follow-up, using lipid values determined within 24h
of admission and lipid values determined between
admission and the follow-up interview, respectively.
The lipid profile included measurement or calcula-
tion of serum levels of total cholesterol, LDL-C, high-
density lipoprotein cholesterol (HDL-C), triglycerides,
and non-HDL-C. The LDL-C target values were as-
signed according to the patient’s cardiovascular risk,
which was determined using two methods. First, pre-
ACS risk status (i.e. very high, high, moderate or low)
was determined for all patients based on selected
patient characteristics, and second, all patients were
classified as being at very high risk because of the
ACS event leading to hospitalization. Target values
Fig. 1 Flowchart for patients in the study. ACS acute coro-
nary syndrome, LLT lipid-lowering therapy, LDL-C low-density
lipoprotein cholesterol
for LDL-C for very high risk, high risk, moderate risk,
and low risk patients were defined according to the
2011 ESC/EAS guidelines as <70mg/dl, <100mg/dl,
<115mg/dl, and <130mg/dl, respectively [4]. Per the
same guidelines, the non-HDL-C target value was
<100mg/dl [4]. The median distance to the LDL-
C target value was calculated for patients who had
not attained the LDL-C target value on the date of
the lipid profile. Attainment of the secondary non-
HDL-C target value (<100mg/dl) was also assessed at
admission and follow-up. Cardiovascular health out-
comes assessed at follow-up were rehospitalization,
MI, stroke, percutaneous coronary intervention, and
coronary artery bypass graft.
Statistical analysis
This study analyzed the ACS patients on LLT at ad-
mission through the follow-up time point. Unless
otherwise specified, the designations of “treated” or
“on LLT” refer to the treatment status at admission,
regardless of the treatment status at follow-up. Demo-
graphic and clinical characteristics, use of cardiovas-
cular medications, and cardiovascular outcomes were
compared between patients on LLT and not on LLT at
admission using χ2 or Mann-Whitney-Wilcoxon tests.
Lipid profiles, LDL-C target value attainment, and
types of LLT used at admission and follow-up were
assessed descriptively in patients on LLT. In all uni-
variate analyses, continuous variables are presented
as means and standard deviations (SDs) or medians
and interquartile ranges (IQRs), and categorical vari-
ables are presented as numbers and/or percentages.
Multivariate logistic regression was used to identify
variables predictive of LDL-C target value attainment
in patients on LLT at admission. Covariates, including
age, gender, obesity, current smoking, sedentary life
style, stable angina, chronic kidney disease, type 2
diabetes mellitus, history of congestive heart failure,
hypertension and statin dose (i. e., atorvastatin dose
equivalent), were chosen based on their potential to
affect LDL-C target value attainment, and no statis-
tical selection methods were applied. Assessment of
cardiovascular outcomes at follow-up was done using
Kaplan-Meier analysis, with P values calculated by
a log-rank test. SAS version 9.3 (Cary, NC, USA) was
used for all calculations. In all analyses, a P value
<0.05 was considered statistically significant.
Results
Characteristics of the study population
The study identified 461 patients hospitalized for ACS
in Germany in 2013–2014 (Fig. 1). The mean (SD)
age of the study population was 64.1 (11.7) years, and
75.5% were male (Table 1). More than half of the pa-
tients had hypertension (80.9%) or documented CHD
(56.9%). The most frequently used types of cardiovas-
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Table 1 Demographic and clinical characteristics of the study populationa
All patients (N= 461) Patients on LLT
(N= 270)
Patients not on LLT
(N= 191)
P valueb
Age, mean (SD) years 64.1 (11.7) 66.4 (10.5) 60.8 (12.6) <0.001
Male 348 (75.5) 212 (78.5) 136 (71.2) 0.07
Obesec 149 (32.4) 100 (37.2) 49 (25.7) <0.01
Hypertension 373 (80.9) 244 (90.4) 129 (67.5) <0.001
Type 2 diabetes mellitusc 133 (29.0) 102 (37.9) 31 (16.3) <0.001
Oral medication for control of diabetes 72 (15.6) 57 (21.1) 15 (7.9) 0.54
Sedentary life stylec 94 (24.5) 49 (21.6) 45 (28.7) 0.11
Current smoker 126 (27.3) 58 (21.5) 68 (35.6) <0.001
Documented CHDc 256 (56.9) 214 (80.8) 42 (22.7) <0.001
History of MIc 133 (30.1) 122 (47.7) 11 (5.9) <0.001
History of CRF/CKD 54 (11.7) 44 (16.3) 10 (5.2) <0.001
Family history of CHDc 191 (48.0) 124 (54.9) 67 (39.0) <0.01
History of stroke (ischemic or hemorrhagic)c 26 (5.9) 21 (8.1) 5 (2.7) <0.05
History of peripheral vascular diseasec 39 (8.6) 32 (12.0) 7 (3.7) <0.01
Type of ACS at admission
STEMI/LBBB MI 142 (30.8) 54 (20.0) 88 (46.1) <0.001
NSTEMI 187 (40.6) 119 (44.1) 68 (35.6) 0.07
Unstable angina 132 (28.6) 97 (35.9) 35 (18.3) <0.001
Medication usec
Beta-blockers 286 (63.1) 220 (81.8) 66 (35.9) <0.001
Calcium channel blockers 79 (17.6) 60 (22.5) 19 (10.4) <0.001
Diuretics 121 (26.7) 93 (34.6) 28 (15.2) <0.001
ACE inhibitors 210 (46.4) 162 (60.2) 48 (26.1) <0.001
Angiotensin receptor blockers 77 (17.1) 51 (19.2) 26 (14.1) 0.16
Acetylsalicylic acid 262 (57.8) 212 (78.5) 50 (27.3) <0.001
Other antiplatelets 90 (19.5) 73 (27.0) 17 (8.9) <0.001
Clopidogrel 49 (10.6) 38 (14.1) 11 (5.8) 0.35
Prasugrel 16 (3.5) 15 (5.6) 1 (0.5) 0.15
Ticagrelor 23 (5.0) 18 (6.7) 5 (2.6) 0.69
Other 2 (0.4) 2 (0.7) 0 (0.0) 0.49
Laboratory values
Hemoglobin A1c, mean (SD) % 6.4± 1.5 6.7± 1.4 6.1± 1.6 <0.01
Serum glucose, mean (SD) mg/dl 131.8± 46.4 133.6± 50.2 129.5± 40.9 0.96
ACS acute coronary syndrome, ACE angiotensin-converting enzyme, CHD coronary heart disease, CKD chronic kidney disease, CRF chronic renal failure,
LBBB left bundle branch block, LLT lipid-lowering therapy, MI myocardial infarction, NSTEMI non-ST elevation myocardial infarction, SD standard deviation,
STEMI ST segment elevation myocardial infarction
aData are presented as numbers and percentages unless otherwise indicated
bP values reflect χ2 or Mann-Whitney-Wilcoxon tests between values for treated and untreated patients
cValues were calculated based on the number of patients with available data rather than the total study or subgroup population
cular medication were beta blockers (63.1%), acetyl-
salicylic acid (57.8%), and ACE inhibitors (46.4%).
Mean (SD) values of hemoglobin A1c and serum
glucose were 6.4% (1.5%) and 131.8 (46.4) mg/dl,
respectively. During the hospital stay, 388 patients
(84.2%) underwent echocardiography, 310 (67.2%) re-
ceived a percutaneous coronary intervention, and 194
(42.1%) underwent coronary angiography (data not
shown).
A total of 270 patients (58.6%) were on LLT at ad-
mission and 191 were not (Fig. 1; Table 1). Patients not
on LLT at hospital admission were younger compared
to those on LLT (60.8 versus 66.4 years, P<0.001) and
had significantly lower rates of obesity (25.7% versus
37.2%, P<0.01), hypertension (67.5% versus 90.4%,
P< 0.001), diabetes (16.3% versus 37.9%, P< 0.001),
documented CHD (22.7% versus 80.8%, P< 0.001),
and history of MI (5.9% versus 47.7%, P< 0.001). The
use of almost all types of cardiovascular medications
was significantly less frequent in patients not on LLT
than those on LLT (Table 1), and patients not on LLT
were more frequently current smokers (35.6% ver-
sus 21.5%, P<0.001) and more often presented with
STEMI/LBBB MI (46.1% versus 20.0%, P< 0.001).
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Table 2 Lipid-lowering
therapy at discharge and
follow-up
Discharge
(N= 270)
Follow-upa
(N= 242)
Statins, n (%) 264 (97.8) 209 (86.4)
Atorvastatin, n (%) 59 (21.9) 52 (21.5)
Mean (SD) dose, mg/day 37± 14 38± 16
Fluvastatin, n (%) 8 (3.0) 7 (2.9)
Mean (SD) dose, mg/day 48± 21 51± 20
Lovastatin, n (%) 0 (0.0) 0 (0.0)
Mean (SD) dose, mg/day – –
Pravastatin, n (%) 10 (3.7) 12 (5.0)
Mean (SD) dose, mg/day 32± 13 31± 12
Rosuvastatin, n (%) 0 (0.0) 0
Mean (SD) dose, mg/day – –
Simvastatin, n (%) 187 (69.3) 134 (55.4)
Mean (SD) dose, mg/day 34± 12 33± 12
Pitavastatin, n (%) 0 (0.0) 0
Mean (SD) dose, mg/day – –
Non-statins, n (%) 22 (8.1) 22 (9.1)
Ezetimibe, n (%) 19 (7.0) 18 (7.4)
Fibrates, n (%) 2 (0.7) 3 (1.2)
Nicotinic acids, n (%) 0 (0.0) 0 (0.0)
Laropiprant, n (%) 0 (0.0) 0 (0.0)
Omega-3 fatty acids, n (%) 1 (0.4) 0 (0.0)
aAlthough 242 patients were included in the follow-up analyses, only 65, 61, 62, 56, and 57 patients had lipid profile
data for total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C, respectively, at follow-up
Table 3 Lipid profiles, dis-
tance to target, and dose
equivalents among treated
patients at admission and
follow-up
Admission
(N= 270)
Follow-upa
(N= 242)
Lipid concentrations, mg/dl
Total cholesterol, mean (SD) 174 (50) 165 (32)
LDL-C, mean (SD) 101 (40) 95 (30)
HDL-C, median (IQR) 43 (36, 50) 50 (40, 59)
Triglycerides, median (IQR) 122 (85, 185) 128 (95, 164)
Non-HDL-C, median (IQR) 121 (98, 152) 115 (98, 143)
Distance to LDL-C <70mg/dl, median (IQR)b 34 (17, 60) 31 (11, 55)
Atorvastatin dose equivalent, mean± SD mg/dayc 18± 12 22± 15
HDL-C high-density lipoprotein cholesterol, IQR interquartile range, LDL-C low-density lipoprotein cholesterol, SD stan-
dard deviation
aAlthough 242 patients were included in the follow-up analyses, only 65, 61, 62, 56, and 57 patients had lipid profile
data for total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C, respectively, at follow-up
bAmong patients not yet attaining the target level
cFor comparison, the simvastatin dose equivalents were 37± 23mg/day at admission and 44± 31mg/day at follow-up
Use of lipid-lowering therapies
Among the 270 treated patients, 97.8% were receiv-
ing statins at admission (Table 2), and the most com-
monly used statins were simvastatin (69.3%) and ator-
vastatin (21.9%; Table 2). In addition, 8.1% of patients
were taking non-statin LLT. At admission, the mean
(SD) atorvastatin dose equivalent was 18 (12) mg/day
(Table 3). At the time of the follow-up interview, only
86.4% of patients on LLT at admission reported taking
statins (Table 2). Simvastatin use decreased to 55.4%
at follow-up, and atorvastatin held steady at 21.5%
(Table 2). The mean (SD) atorvastatin dose was 22
(15) mg/day (Table 3).
Lipid profiles and lipid target value attainment
At admission, mean (SD) total cholesterol and LDL-
C levels in patients on LLT were 174 (50) mg/dl and
101 (40) mg/dl, respectively (Table 3). Median (IQR)
HDL-C, triglyceride, and non-HDL-C levels were 43
(36–50) mg/dl, 122 (85–185) mg/dl, and 121 (98–152)
mg/dl, respectively. Among the 242 patients with fol-
low-up data, values for total cholesterol, LDL-C, and
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Fig. 2 LDL-C target value
attainment, by a pre-ACS
risk level and b time point.
a Risk levels were deter-
mined using chart data from
the pre-ACS period. LDL-
C targets were as follows:
very high risk, <70mg/dl;
high risk, <100mg/dl; mod-
erate risk, <115mg/dl; and
low risk, <130mg/dl. bGoal
attainment is shown in a ker-
nel density plot for the sub-
group of 61 treated patients
for whom LDL-C data were
available at both admis-
sion (blue line) and follow-
up (green line). The X-axis
shows LDL-C levels and the
Y-axis shows the percent-
age of patients. Follow-up
data were collected 120
days after admission to
the hospital. LDL-C low-
density lipoprotein choles-
terol
non-HDL-C decreased at follow-up, while the levels of
HDL-C and triglycerides increased (Table 3).
At admission, 27.8% of treated patients had at-
tained the non-HDL-C target, and 31.6% had done so
by the follow-up assessment (data not shown). Among
treated patients with very high pre-ACS risk (N= 203),
only 24.6% attained LDL-C target values at admission
(Fig. 2a). The LDL-C target value attainment rates
for patients classified pre-ACS as high, moderate, and
low risk were 37.5%, 62.1%, and 80.0%, respectively
(Fig. 2a).
When all patients on LLT (N= 270) were classified as
very high risk because of their hospitalization for ACS,
21.9% had attained the LDL-C target value at admis-
sion (data not shown). Among those not attaining the
LDL-C target, the median (IQR) distance to the target
value at admission was 34 (17–60) mg/dl (Table 3). At
the time of follow-up, 61 treated patients had data for
LDL-C at both admission and follow-up, and 19.7% of
them had attained the LDL-C target value (Fig. 2b).
Among these 61 patients, target value attainment at
admission was 19.7% (Fig. 2b). Among treated pa-
tients not attaining the LDL-C target value at follow-
up, the median (IQR) distance to the target was 31
(11–55) mg/dl (Table 3).
In multivariate regression analyses of LDL-C tar-
get value attainment (Table 4), chronic kidney disease
was associated with 3-fold higher odds of attainment
(odds ratio OR 3.12, 95% CI 1.29–7.55), while current
smoking was associated with a 77% lower likelihood
of attaining the LDL-C target value (OR 0.23, 95% CI
0.07–0.72).
Discussion
The DYSIS II assessed lipid profiles and LDL-C target
value attainment longitudinally in patients receiving
LLT who were hospitalized for ACS in Germany. Ap-
proximately 20% of treated German ACS patients with
data at both admission and follow-up attained the
recommended LDL-C level of <70mg/dl, with no ap-
parent gains between hospitalization and follow-up.
Over the same time interval, triglyceride levels actu-
ally increased. These findings suggest potential rea-
sons for such poor outcomes: LLT at admission con-
sisted mainly of statin monotherapy (primarily sim-
vastatin), and the mean atorvastatin dose equivalent
increased only slightly, from 18 to 22mg/day, between
admission and follow-up.
According to the 2011 ESC/EAS guidelines [4] and
the more recently published 2016 ESC/EAS guidelines
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Table 4 Predictors of LDL-
C target value attainment in
patients on LLT at admissiona
Odds ratio 95% CI P-value
Age ≥70 years 0.71 0.33–1.52 0.376
Female 1.39 0.59–3.32 0.454
BMI >30kg/m2 0.98 0.44–2.17 0.960
Current smoking 0.23 0.07–0.72 0.012
Sedentary life style 0.70 0.29–1.69 0.426
Chronic kidney disease 3.12 1.29–7.55 0.012
Type 2 diabetes mellitus 1.18 0.54–2.59 0.680
History of congestive heart failure 1.16 0.34–3.96 0.819
Hypertension 0.51 0.17–1.55 0.235
Statin dose (atorvastatin dose equivalent, mg/day) 1.02 0.988–1.05 0.220
BMI body mass index, CI confidence interval
aBold print indicates statistical significance
[12], all patients experiencing an ACS event should
receive pharmacologic treatment. The EUROASPIRE
surveys I–III showed that between 1995 and 2007 rates
of treatment for lipid abnormalities among German
patients with coronary events increased from 35.0%
to 87.0% (P< 0.001) [5]. Other studies of German pa-
tients hospitalized for an ACS event (STEMI, NSTEMI,
or unstable angina) reported statin treatment rates at
discharge ranging from 73% to 94.6% [13–16]; how-
ever, EUROASPIRE IV found that in Germany low/
moderate-intensity LLTs are much more frequently
used than high-intensity LLTs [17], consistent with our
finding that simvastatin was the most commonly used
LLT in DYSIS II. Other studies have found that sim-
vastatin is the most commonly prescribed statin in
Germany [8–10] and that non-statins are used infre-
quently for lipid control [8, 9]. The 2016 ESC/EAS
guidelines state that lipid values should be re-evalu-
ated 4–6 weeks after ACS to determine whether lipid
goals have been reached and if the therapeutic reg-
imen needs to be adapted [12]. In this study only
a slight increase in dose strength was noted, from
18 to 22mg/day, between admission and follow-up
(120± 15 days after admission). Very often statin treat-
ment initiated during the hospital stay is done so with
low dosages and is expected to be up-titrated during
follow-up. Our data indicate that this up-titration is
not taking place. Use of less effective LLTs and failure
to increase the dose potency after a coronary event
may explain the low attainment of the LDL-C target
value in German ACS patients.
As has been elucidated in the past [8], office-based
physicians in Germany will likely not intensify LLT
in most cases after discharge from hospital. It is
therefore proposed to discharge patients post-ACS
with high intensity LLT, including a potent statin and
ezetimibe. The newly available PCSK9 inhibitors are
an additional option to treat ACS patients, but the
use of this therapy is limited in Germany. Before
using a PCSK9 inhibitor, all other available therapeu-
tic options must be exhausted, e.g., use of a potent
statin (e.g., 40mg atorvastatin) and the combination
with ezetimibe. Consistent use of this strategy would
bring most patients to the treatment goal. Addition-
ally, clear advice in the discharge letter concerning
the treatment goal and the therapeutic options could
help general practitioners in the clinical setting to
optimize the patients’ therapy. The ACS patients in
Germany should also be encouraged to take part in re-
habilitation programs after an acute event to improve
the individual prognosis. In terms of identifying those
patients at highest risk, the validated TRS2P score
provides a modern and easy to use tool [18].
Among patients with data at both admission and
follow-up, the LDL-C target value attainment rate in
the German ACS cohort of DYSIS II did not change
from hospital admission to follow-up. In part because
previous studies of lipid target value attainment in
Germany have used different targets, the reported
rates of attainment are somewhat higher than in
DYSIS II. The DYSIS applied a target of <100mg/dl
to high-risk statin-treated patients, and accordingly
41.9% of high-risk patients, as well as 47.3% of pa-
tients with cardiovascular disease, attained the target
value [9]. Other studies applying the <100mg/dl tar-
get to statin-treated patients in Germany have found
LDL-C target value attainment rates of ~43–50% [8,
19]. Similarly, among German patients undergoing
inpatient cardiac rehabilitation after hospitalization
for an acute coronary event, 69.6% attained an LDL-
C level <100mg/dl by the discharge date [14]. To our
knowledge, DYSIS II is the first study to assess attain-
ment of the more stringent <70mg/dl target value in
ACS patients in Germany.
The only variable positively associated with LDL-
C target value attainment in the current study was
chronic kidney disease, which was associated with
3-fold higher odds of attainment. According to the
2016 ESC/EAS guidelines, patients with chronic kid-
ney disease are considered as high-risk or very high-
risk patients and should be treated accordingly [12].
Because these patients are treated as high or very high
risk, regardless of LDL-C values, it is possible that the
more aggressive treatment protocol resulted in higher
odds of LDL-C attainment. Smoking, on the other
hand, was associated with a 77% lower likelihood of
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attaining the LDL-C target value. This result is consis-
tent with the results from the German cohort of DYSIS,
which found smoking to be associated with higher
odds of LDL-C non-attainment in statin-treated pa-
tients [9].
One limitation of this study is that adherence to
treatment was not directly assessed. Although most
patients reported receiving a statin prescription at fol-
low-up, actual medication-taking behavior was not
queried. Previous studies in Germany suggest that
adherence to statins falls by 20–35% within the first
year of use [13, 19, 20]. Secondly, a follow-up of
120± 15 days was too short to observe any changes in
therapy or cardiovascular outcomes. A long-term fol-
low-up of the patients would be of interest to evaluate
any changes of therapy in the longer term of the dis-
ease. Per the findings of de Lemos et al. [21], the effect
of statin treatment on cardiovascular event risk reduc-
tion may not be evident until more time has passed.
Finally, data collection by telephone at follow-up may
not have been as accurate as the medical chart review
used for data collection at admission andmay have af-
fected the direction and degree of changes observed
over time.
In conclusion, this study of the German ACS cohort
of DYSIS II showed that LDL-C target value attainment
is suboptimal among very high-risk patients on LLT.
Hospitalization for an ACS event did not greatly alter
lipid management in ACS patients. Both LLT doses
and rates of LDL-C target value attainment remained
essentially the same several months after the event.
These results indicate that LLTs are not utilized in an
efficient manner in ACS patients in Germany, allow-
ing cardiovascular mortality to remain high. An LLT
should be administered according to the latest guide-
lines, i. e., with higher doses and combination thera-
pies, in order to help patients attain their LDL-C target
value and reduce their risk of cardiovascular events.
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